Interleukin-6 transcripts up-regulation in lymph nodes from unicentric and multicentric Castleman disease

Marco Lucioni1,2, Gaia Morello3, Caterina Cristinelli1

  • 1Department of Molecular Medicine University of Pavia Pavia Italy.

Ejhaem
|December 18, 2024
PubMed

Insights

Castleman disease (CD) involves elevated Interleukin-6 (IL-6) in lymph nodes. Endothelial cells are identified as a key source of this IL-6 production in CD patients.

Area of Science:

  • Hematology
  • Immunology
  • Pathology

Background:

  • Castleman disease (CD) is a group of lymphoproliferative disorders with varied symptoms.
  • Interleukin-6 (IL-6) is a key cytokine implicated in CD's inflammatory processes.
  • The cellular origin of IL-6 in CD's microenvironment remains unclear.

Purpose of the Study:

  • To investigate the cellular source of IL-6 in Castleman disease lymph nodes.
  • To quantify IL-6 expression across different CD subtypes and controls.

Main Methods:

  • RNAscope analysis and dual in situ hybridization/immunohistochemistry were used.
  • Five nodal CD cases (UCD, iMCD, HHV8+ MCD, HIV+ HHV8+ MCD) and a control were analyzed.
  • Quantitative mRNA analysis was performed using HISTOQUANT software.

Main Results:

  • Increased IL-6 expression was observed in all CD lymph nodes.
  • HHV8+ cases showed the highest IL-6 levels, with significant differences compared to controls.
  • IL-6 was consistently overexpressed in CD31-positive endothelial cells in all tested CD cases.

Conclusions:

  • Endothelial cells are likely a major source of IL-6 in the nodal microenvironment of CD.
  • A trend of increased IL-6 was noted in UCD and iMCD, while HHV8+ MCD showed significant upregulation.
  • Findings highlight the role of endothelial IL-6 in CD pathogenesis.
Abstract